Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma

Researchers comparing outcomes of 230 patients with myeloma or lymphoma who underwent autologous hematopoietic cell transplantation (HCT) on an inpatient vs. outpatient basis within a single transplant program have found comparable outcomes in the two cohorts. All patients had an autologous transplant between 2009 and 2012 at the Medical College of Wisconsin (MCW). Outpatient transplant patients were treated at an MCW cancer center day hospital and were evaluated daily by transplant center staff. Two-year progression-free survival was 62% for outpatient vs. 54% for inpatient cohorts (p=0.155). One- and two-year overall survival was 97% and 83% for outpatient vs. 91% and 80% for inpatient, respectively (p=0.271). The researchers concluded that “with daily outpatient evaluation and aggressive supportive care, outpatient autologous HCT can result in excellent outcomes for myeloma and lymphoma patients.”

Graff TM, et al. Bone Marrow Transplant

Patient-level summary of this study (PDF)

Related Resources